

Psilocybin Patient Qualification & Safety Committee Meeting Minutes and Chat:

Location: Teams

Date: 04/20/2026

Time: 09:00

Attendance: Johnathan Mouchet, Jorge Gonzales, Brenda Martinez, Dominick Zurlo, Cathy Augeri, Adrian Estrada, Ian Dunn, Raymond Gallegos, Chris Peskuski, Cyrus Rautman, Brenda Burgard, Kate Hawke, Eileen Brewer, Leslie Peterson, Skye Rivers, DezBaa', Gregory Evans, James Brown, Catherine Warnock, Robert Truckner.

Minute Taker: Ismail Zoutat

**This meeting was recorded. For specific details pertaining to the meeting, please refer to the recording located on the Medical Psilocybin Advisory Board Website: [Psilocybin Advisory Board](#)*

Agenda items

1. Opening Statements

- Meeting called to order, recording confirmed.
- Dominick Zurlo welcomed attendees and reminded group to use appropriate language due to recording.
- Announced statewide ADA-compliance updates may temporarily remove documents from the website; requests should be limited to urgent needs.
- Noted potential website access issues between April 24–26.
- Confirmed this is the Patient Qualification & Safety Committee meeting, chaired by Ian Dunn.
- Ian greeted participants and outlined agenda.

2. Introductions

- Participants introduced themselves with role/expertise:
 - Sky Rivers – Santa Fe Reporter; retired intuitive counselor; following program updates.

- Kate Hawke – Trauma therapist; MAPS member; assisting with Phase I FDA study in Scottsdale.
- Chris Peskuski – Veteran facilitator, Colorado.
- Brenda Burgard – Chair of Training & Education
- Gregory Evans – Independent researcher/mycologist.

3. Agenda Review

- Agenda items reviewed by Ian:
 - Patient Information Safety
 - Petition Submission Process
 - Evidence Review Standards

4. Patient Information Safety

- Summary of Proposed Standards
 - Align confidentiality protections with HIPAA.
 - Limit disclosures to minimum necessary.
 - No disclosure of patient information without valid legal process.
 - Notify patients before disclosure when possible.
 - Applies to all licensees, regardless of federal HIPAA status.
- Discussion
 - Dominic recommended:
 - Removing HIPAA year reference (due to updates).
 - Adding HITECH for security rule coverage.
- Vote:
 - 4 Yes/ 0 No –Adopted.

5. Petition Submission Process

- Key Recommendations

- Board begins accepting petitions February 28, 2027.
- Committee provides initial qualifying condition recommendations by January 31, 2027.
- Petitions:
 - Submitted electronically to DOH.
 - Must use subject line: “Petition to the Medical Psilocybin Advisory Board.”
 - Must begin with: “Dear Medical Psilocybin Advisory Board.”
 - Must be submitted 30 days before a meeting (35 days for public notice inclusion).
- Required petition contents:
 - Contact info
 - Proposed condition
 - TOC, narrative, statement of benefit
 - Supporting evidence, optional additional materials
- Discussion
 - Sky Rivers asked whether this changed the program’s implementation date (December 2026).
 - Ian clarified: **No**, implementation timing stays the same; this is only scheduled for when petitions for *additional* conditions begin.
 - Kate Hawke confirmed this petition process applies only to **new** conditions beyond the four already legislated.
- Vote:
 - 6 Yes / 0 No – Adopted

6. Evidence Review Standards

- Proposed standards:

- RCTs considered strongest evidence.
- If RCTs unavailable: high quality observational/open label studies acceptable with caution.
- Systematic reviews allowed but must avoid double weighting underlying studies.
- Considerations include:
 - Strength/consistency of evidence
 - Effect size and clinical relevance
 - Known or potential risks
 - Severity of condition & alternative treatment option
- Discussion
 - Clarified standards apply only to new conditions not end of life care already designated.
- Vote:
 - 4 Yes/0 No: Adopted.

7. Next Meetings & Future Work

- The following conditions were discussed during discussion as candidates for future review:
 - Major Depressive Disorder (MDD)
 - Chronic pain
 - Traumatic Brain Injury (TBI)
 - Parkinson's disease
 - Alzheimer's disease
 - Fibromyalgia
 - Cluster headaches (noted as having strong research)
 - Prolonged grief disorder (suggested as the correct clinical framing)

- Existential distress (including non end of life existential injury)
- Demoralization (cited from emerging research)
- Postpartum depression
- Eating disorders
- Autism (with social anxiety components)
- Nicotine use disorder (noted that studies exist; may qualify depending on DOH)
- Autoimmune conditions including Lyme disease
- Moral injury (noted as widespread but lacking substantial research)

8. Conditions prioritized for next deep dive meeting

- Major Depressive Disorder
- Neurological conditions such as Alzheimer's and Parkinson's

9. Next Meeting

- May 4, 2026 – 9:00 to 11:00 AM, confirmed by DOH.

10. Meeting Adjourned

Committee Chat

Reminder:

This meeting is being recorded

Please remember to keep language appropriate as the recordings are made public on the Advisory Board Website

Contact information:

Email: Medical.Psilocybin@doh.nm.gov

Program Website: <https://www.nmhealth.org/about/mcpp/mpp/>

Advisory Board Website: <https://www.nmhealth.org/about/mcpp/mpp/mpab/>

Link directly to the statute:

<https://nmonesource.com/nmos/nmsa/en/item/4355/index.do#a2D>

How to raise your hand to speak: If on a ... by Gonzales, Jorge, DOH

Yesterday 9:05 AM

Gonzales, Jorge, DOH

How to raise your hand to speak:

If on a computer – click on the “hand” icon near the top of the Teams window (it says “Raise” under the icon)

If on the Teams app on a phone, please press the ellipses (three dots) in the menu and then the “hand” icon will appear, and you can select it

Graphical user interface, application

AI-generated content may be incorrect.

Graphical user interface, application

AI-generated content may be incorrect.

If you are joining through voice only on a phone, press *5 to raise or lower your hand

How to Unmute:

Once your name is called, you will be able to unmute:

To unmute/mute on Teams on a Computer or on the Teams Phone App click on the microphone icon:

Graphical user interface, text, application

AI-generated content may be incorrect.

On a computer it is in the upper right area of the Teams window.

On a phone it is usually in the lower left of the Teams App, however, different models of phone (Apple, Android, etc...) may have the mute/unmute icon in a different location:

Telephone: voice only - press *6 to unmute/mute

Petition Submission Process Adopted: XX-X... by G-Ian.Dunn

G-Ian.Dunn

Yesterday 9:13 AM

Petition Submission Process

Adopted: XX-XX-XXXX

Purpose and Initial Implementation

To prevent program overload at initial implementation, the Committee recommends that the Board not begin accepting petitions until February 28, 2027.

Prior to the acceptance of petitions, the Patient Qualification and Safety Committee should evaluate potential qualifying conditions and provide the Board with an initial set of expansionary qualifying condition recommendations no later than January 31, 2027.

Authority to Accept Petitions

Once the Board begins accepting petitions:

The Medical Psilocybin Advisory Board may accept and review petitions from any individual or association of individuals requesting the addition of a qualifying conditions under the Medical Psilocybin Act.

Submission Method

Except as otherwise provided, all petitions shall be submitted electronically to medical.psilocybin@doh.nm.gov

Subject Line:

PETITION TO THE MEDICAL PSILOCYBIN ADVISORY BOARD

Message Body:

“Dear Medical Psilocybin Advisory Board,”

(Petition Materials Attached)

Submission Deadlines:

Complete petitions may be submitted at any time following February 28, 2027.

Petitions will be scheduled for review at the next available Board meeting.

To be considered:

Petitions must be received at least 30 calendar days prior to the scheduled meeting; and

To ensure inclusion in the public notice petitions must be received at least 35 calendar days prior to the Board meeting

To be processed and forwarded to the Board, petitions must be submitted in a readable electronic format and include the following:

Caption

Name, address, and telephone number of the petitioner

The medical condition, medical treatment, or disease proposed for inclusion

Table of Contents

An organized index of all materials included in the petition

Introductory Narrative

Identification of the individual or association submitting the petition

Description of the petitioner's interest (e.g., professional, personal, or public interest)

Statement of Proposed Benefit

Explanation of the anticipated therapeutic benefit of psilocybin specific to the condition

Supporting Evidence

Relevant scientific literature, clinical data, or other documentation

Copies of all cited materials

Additional Materials (Optional)

Testimonials or other supporting documentation deemed relevant by the petitioner

Evidence Review Standards for Qualifying Co... by Gonzales, Jorge, DOH

Yesterday 9:18 AM

Gonzales, Jorge, DOH

Evidence Review Standards for Qualifying Conditions

Adopted: XX-XX-XXXX

Purpose:

To ensure that recommendations for new qualifying conditions under the Medical Psilocybin Program are based on credible scientific evidence, clinical relevance, and patient safety considerations.

Scope:

This policy governs the evaluation of potential qualifying conditions by the Patient Qualification and Safety Committee.

Standard of Evidence

Randomized controlled trials shall be considered the strongest and most reliable form of evidence for evaluating therapeutic benefit and shall be prioritized when available.

In the absence of sufficient randomized controlled trial data, the Committee may consider high-quality observational studies, open-label trials, and other emerging evidence, provided that:

Limitations are clearly acknowledged; and

The totality of evidence supports a reasonable expectation of benefit and safety.

Systematic reviews and meta-analyses may be used to evaluate consistency and overall trends in the evidence. The Committee shall ensure that such analyses are not given duplicative weight where they rely on the same underlying studies already under review

In applying the standard of evidence, the Committee shall consider:

The strength and consistency of findings across studies

The size and clinical relevance of observed effects

Known or potential risks associated with treatment

The severity of the condition and availability of alternative treatments

Can you Zoom into the document please Jorge by Chris Peskuski

Chris Peskuski

Yesterday 9:20 AM

Can you Zoom into the document please Jorge

How to submit written public comments: Pl... by Gonzales, Jorge, DOH

Yesterday 9:24 AM

Gonzales, Jorge, DOH

How to submit written public comments:

Please send written public comment to the program email at:
medical.psilocybin@doh.nm.gov and include the committee's name in the subject line.

If referencing documents from other sources/websites:

Do not include the document, only a working - accessible hyperlink;

Documents must be sent with context provided (i.e. do not simply send a research article);

The comment must relate to the topics discussed in the meeting.

Documents are limited to no more than 3 pages (letter size) in length and must be in 10-point font or larger.

Please remember to include your full, legal name and any organizational affiliations you may be representing (if any) on the documents.

To be included, please send your comment by 5:00 PM the business day after the meeting.

But until the FDA approves this, to my unde... by Skye Rivers

Skye Rivers

Yesterday 9:26 AM

But until the FDA approves this, to my understanding there is no insurance coverage.

Oh this is not insurance related, but HIPA by Skye Rivers

Skye Rivers

Yesterday 9:28 AM

Oh this is not insurance related, but HIPA

HIPAA by Skye Rivers

Skye Rivers

Yesterday 9:28 AM

HIPAA

1 Like reaction.

Pain was actually the number one most repor... by Eileen Brewer

Eileen Brewer

Yesterday 9:31 AM

Pain was actually the number one most reported complaint in the year leading up to suicide among veterans, not depression or PTSD

and there is a ton of evidence that pain ca... by Eileen Brewer

Eileen Brewer

Yesterday 9:32 AM

and there is a ton of evidence that pain can be treated with psychedelics, often without Assisted Therapy

fibro might fall under the umbrella of chro... by Eileen Brewer

Eileen Brewer

Yesterday 9:33 AM

fibro might fall under the umbrella of chronic pain. important to consider what that means

headache diseases, especially migraine and ... by Eileen Brewer

Eileen Brewer

Yesterday 9:33 AM

headache diseases, especially migraine and cluster headache are not traditionally considered chronic pain conditions, but there are successful clinical trials for the treatment of those conditions with psilocybin

Prolonged grief disorder is a diagnosis by Kate Hawke

Kate Hawke

Yesterday 9:34 AM

Prolonged grief disorder is a diagnosis

@catherine - Demoralization by Evans, Gregory, DPS

Evans, Gregory, DPS

Yesterday 9:35 AM

@catherine - Demoralization

Tobacco addiction is a major deadly conditi... by Kate Hawke

Kate Hawke

Yesterday 9:36 AM

Tobacco addiction is a major deadly condition with good initial research results

"qualifying condition" includes: (1) majo... by Gonzales, Jorge, DOH

Yesterday 9:36 AM

Gonzales, Jorge, DOH

"qualifying condition" includes:

(1) major treatment-resistant depression;

- (2) posttraumatic stress disorder;
- (3) substance use disorders;
- (4) end-of-life care; and
- (5) other conditions approved by the department;

1 Like reaction.

But also some evidence for phantom limb pai... by Eileen Brewer

Eileen Brewer

Yesterday 9:37 AM

But also some evidence for phantom limb pain, spinal chord injuries, low back pain, CRPS, cancer pain, neuropathic pain

1 Like reaction.

also, infection acquired chronic illeness by Eileen Brewer

Eileen Brewer

Yesterday 9:37 AM

also, infection acquired chronic illeness

illness by Eileen Brewer

Eileen Brewer

Yesterday 9:38 AM

illness

autoimmune and inflammatory conditions by Eileen Brewer

Eileen Brewer

Yesterday 9:38 AM

autoimmune and inflammatory conditions

yes - all Neurodivergence by Evans, Gregory, DPS

Evans, Gregory, DPS

Yesterday 9:38 AM

yes - all Neurodivergence

especially lyme by Eileen Brewer

Eileen Brewer

Yesterday 9:38 AM

especially lyme

but it is REALLY important to understand th... by Eileen Brewer

Eileen Brewer

Yesterday 9:39 AM

but it is REALLY important to understand that the treatment protocols being researched for these conditions are sooooo different from what is being used to treat depression, PTSD, SUD, etc.

and if we lead people to believe that they ... by Eileen Brewer

Eileen Brewer

Yesterday 9:40 AM

and if we lead people to believe that they can receive treatment for these conditions in the same way as mental health, they may become more hopeless when their results aren't good

One additional caveat - sessions must take ... by Zurlo, Dominick, DOH

Zurlo, Dominick, DOH

Yesterday 9:42 AM

One additional caveat - sessions must take place at "approved locations" as required in the statute.

1 Like reaction with medium light skin tone.

I understand the current restrictions, and ... by Kate Hawke

Kate Hawke

Yesterday 9:45 AM

I understand the current restrictions, and I appreciate considering how microdosing will eventually fit into our system. People are already doing it on their own so I hope we can provide guidance and support.

1 Heart reaction.

with any quaifying condition, it will need ... by Skye Rivers

Skye Rivers

Yesterday 9:46 AM

with any quaifying condition, it will need to be backed up by a doctor treating the person correct?

documentation backing up conditions will be... by Skye Rivers

Skye Rivers

Yesterday 9:46 AM

documentation backing up conditions will be required

Yes! by Eileen Brewer

Eileen Brewer

Yesterday 9:48 AM

Yes!